QJM: An International Journal of Medicine
Goldstein, Mark R.; Poland, Gregory A.; Graeber, Charles W.
Introduction
Prevalent comorbidities for the development of severe pneumonia requiring intensive care unit treatment, acute respiratory distress syndrome (ARDS), and death from Coronavirus disease 2019 (COVID-19) include hypertension, diabetes and cardiovascular disease [1,2]. We posit that drugs commonly used in the treatment of those comorbidities may actually increase the risk of severe pneumonia, ARDS and mortality in the setting of COVID-19; the drugs of primary concern include angiotensin receptor blockers (ARBs) used for blood pressure lowering and statins used for cholesterol lowering.
Keywords
COVID-19, SARS-CoV-2, Treatment